Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 197-204

  Levin, Myron J ^a,j   Moscicki, Anna Barbara ^b   Song, Lin Ye ^c   Fenton, Terrence ^c   Meyer, William A ^d   Read, Jennifer S ^e   Handelsman, Edward L ^f   Nowak, Barbara ^g   Sattler, Carlos A ^h   Saah, Alfred ^h   Radley, David R ⁱ   Esser, Mark T ⁱ   Weinberg, Adriana ^a  

^a Nutrition Obesity Research Center at the University of Colorado   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ PPD Vaccines and Biologics Laboratory   (United States)

^j UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

HIV infection; HPV antibody response; HPV vaccine

Indexed keywords

PLACEBO; VIRUS ANTIBODY; VIRUS RNA; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILD; CONJUNCTIVITIS; COUGHING; CREATININE BLOOD LEVEL; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; GASTRITIS; GLUCOSE BLOOD LEVEL; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INJECTION SITE REACTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; NOSE CONGESTION; OTITIS; PAIN; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PYODERMA; RASH; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; SINUSITIS; SKIN INFECTION; SWELLING; THORAX PAIN; THROMBOCYTE COUNT; TOOTH PAIN; URINARY TRACT INFECTION; VIRUS LOAD; WHEEZING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; PAPILLOMA VIRUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CHILD; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; VIRAL LOAD;

EID: 77957311616     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181de8d26     Document Type: Article

References (43)

1. Parkin M, Bray F. The burden of HPV-related cancer. Vaccine. 2006;24 (Suppl 3):S11-S25.
2. Munoz N, Castellsagué X, Berrington de González A, et al. HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S1-S10.
3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
4. Lacey CJN, Lowndes CM, Shah KV. Chapter 4. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2004;24(Suppl 3):S35-S41.
5. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.
6. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-226.
7. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
8. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002;325:572-574.
9. Palefsky JM, Gillison ML, Strickler HD. Chapter 16. HPV vaccines in immunocompromised women and men. Vaccine. 2006;24(Suppl 3): S140-S146.
10. Moscicki AB, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 2004;190: 37-45.
11. Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis. 2004;190:1413-1421.
12. Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003;188:128-136. (Pubitemid 36829752)
13. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92: 1500-1510.
14. Dolev JC, Maurer T, Springer G, et al. Incidence and risk factors for verrucae in women. AIDS. 2008;22:1213-1219.
15. De Panfilis G, Melzani G, Mori G, et al. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis. 2002;29:121-125.
16. The Future II Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356: 1915-1927.
17. Harper DM, Franco EI, Wheeler C, et al. Efficacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364:1757-1765.
18. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943. (Pubitemid 46740303)
19. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three clinical trials. Lancet. 2007;369: 1693-1702.
20. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet. 2007; 369:1861-1868.
21. Giuliano A, Palefsky J. The efficacy of quadrivalent HPV (types 6/11/16/ 18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. EUROGIN, November 10, 2008, Nice, France. Abstract# SS19-7a.
22. Palefsky J, Giuliano A. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. EUROGIN, November 13, 2008, Nice, France. Abstract# PS1-3a.
23. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10:108-115.
24. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12:959-969.
25. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-2145.
26. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect Dis J. 2007;26:201-209.
27. Merck & Co., Inc. 2009. GARDASIL product information. Merck & Co., Inc., Whitehouse Station, NJ.
28. Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(Suppl 3):S106-S113.
29. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol. 2008;110:S1-S10.
30. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553-11557.
31. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(Suppl 3):S106-S113.
32. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
33. Olsson S-E, Vulla LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-4939.
34. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev. 2005;14:283-288.
35. Levin MJ, Gershon AA, Weinberg A, et al; and the ACTG 265 Team. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310.
36. Levin MJ, Song L-Y, Fenton T, et al; for the Infant, Maternal, Pediatric, Adolescent AIDS Clinical Trials P1057 Team. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008;26:4210-4217.
37. Moir S, Ho J, Malasipina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIVinfected viremic individuals. J Exp Med. 2008;205:1797-1805.
38. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIB-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A 2006;103:2262-2267.
39. DeMilito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180-2186.
40. Hart M, Steel A, Clark SA, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol. 2007; 178:8212-8220.
41. Jiang W, Lederman MM, Mohner RJ, et al. Impaired naïve and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol. 2008;82:7837-7845.
42. Abzug MJ, Pelton SI, Song L-Y, et al; for the P1024 Protocol Team. Immunogenicity and safety of and predictors of response to a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy (Pediatric AIDS Clinical Trials Group P1024). Pediatr Infect Dis J. 2006;25:920-929.
43. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis. 2006;193:302-311.